PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32321460-0	2020	Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.	Sunitinib	91-100	adhesion G protein-coupled receptor L4	Homo sapiens	18-23	
32321460-9	2020	RESULTS: Patients with high ELTD1 expression in the tumor vasculature experienced a significantly better progression free survival (PFS) with sunitinib treatment as compared to patients with low ELTD1 expression (8 versus 5.5 months, respectively).	Sunitinib	142-151	adhesion G protein-coupled receptor L4	Homo sapiens	28-33	
32321460-12	2020	CONCLUSIONS: Our results identify tumor vessel ELTD1 expression as a positive predictive marker for sunitinib-treatment in patients suffering from mRCC.	Sunitinib	100-109	adhesion G protein-coupled receptor L4	Homo sapiens	47-52